<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025475</url>
  </required_header>
  <id_info>
    <org_study_id>17-2871</org_study_id>
    <nct_id>NCT05025475</nct_id>
  </id_info>
  <brief_title>Stitch Closure of PFO and Septal Repair (STITCH)</brief_title>
  <official_title>Suture Mediated Septal Defect Closure/Repair Evaluation of the NobleStitch EL System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobles Medical Technologies II Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobles Medical Technologies II Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch™&#xD;
      EL versus FDA approved Amplatzer Occluder device for closure of Patent Foramen Ovale to&#xD;
      prevent recurrent ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate non-inferiority of the NobleStitch™ EL with medical management in both safety&#xD;
      and effectiveness compared to the FDA-approved Amplatzer occluder with medical management for&#xD;
      PFO closure.&#xD;
&#xD;
      To demonstrate that the NobleStitch™ EL does not increase the incidence of ischemic stroke&#xD;
      compared to published medical management data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non-randomized, single-center, observational study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Closure Rates of PFO and ASD</measure>
    <time_frame>12 months</time_frame>
    <description>Saline Contrast Echo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent Stroke Rate</measure>
    <time_frame>4-6 weeks, 6 months, 1 year, and annualy up to five years</time_frame>
    <description>Rate of which Patient Experiences Recurrent Stroke</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Migraine</measure>
    <time_frame>4-6 weeks, 6 months, 1 year, and annually up to five years</time_frame>
    <description>Rate of Patients who have Experience Improvement in Migraine</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Foramen Ovale, Patent</condition>
  <condition>Septal Defect, Atrial</condition>
  <condition>Septal Defect, Heart</condition>
  <arm_group>
    <arm_group_label>PFO Closure Rate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), transseptal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present), and rate of a recurrent neurologic embolic event in patients with cryptogenic stroke and PFO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Published PFO Device Closure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NobleStitch EL</intervention_name>
    <description>Closure of PFO using NobleStitch EL Closure System</description>
    <arm_group_label>PFO Closure Rate</arm_group_label>
    <other_name>Suture Mediated PFO Clsoure and Septal Repair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amplatzer</intervention_name>
    <description>Closure of PFO with FDA approved Amplatazer PFO closure device</description>
    <arm_group_label>Published PFO Device Closure</arm_group_label>
    <other_name>Closure of PFO using septal occluder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PFO&#xD;
&#xD;
          -  ASD (less than 1 cm with redundant septal tissue)&#xD;
&#xD;
          -  Trans Septal Puncture Sites&#xD;
&#xD;
          -  ASA (when an appropriate PFO or small ASD defect is present)&#xD;
&#xD;
          -  Stroke&#xD;
&#xD;
          -  Trans Ischemic Attack (TIA)&#xD;
&#xD;
          -  Platypnea Orthodeoxia Syndrome&#xD;
&#xD;
          -  Decompression Illness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years and over 65 years of age&#xD;
&#xD;
          -  Patients who are not fluent in English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony A Nobles, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nobles Medical Technologies II Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inova Health Care</name>
      <address>
        <city>Fairfax</city>
        <state>California</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

